Sun Pharmaceutical Industries Limited
PharmaMumbai, India, India · Est. 1983 · 24,000 employees
Sun Pharmaceutical Industries Limited is a global pharmaceutical company focused on developing and manufacturing specialty generic and branded medications across multiple therapeutic areas.
1
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
2
Indications↗
Distinct diseases across all programs
58
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
1 drugs in development
Phase 21
Phase 11
By Therapeutic Area
top 2
Metabolic & Endocrine
150%
Nephrology
150%
R&D Momentum
45/100
Pipeline Velocity
11/100
Trial Completion Rate
78/100
Pipeline Concentration
50/100
Pipeline Freshness
65/100
Strategic Signals
- ↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity
Activity
Key Events
Feb 25, 2026TrialStudy to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
Jan 20, 2026TrialEfficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
Mar 21, 2025TrialA Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
Jul 1, 2024TrialA Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
Feb 29, 2024TrialA Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients
Nov 27, 2023TrialA Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients
Nov 15, 2023TrialA Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne
Nov 15, 2023TrialA Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne
4 more events
Sep 1, 2023TrialA Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne
Jun 30, 2022TrialLong Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
Dec 20, 2021TrialA Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Jul 30, 2021TrialTo Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis
Details
Company Info
Company Overview
$18.5B
Mkt Cap
$4.8B
Revenue
—
Cash
CEODilip Shanghvi
Founded1983
Employees24,000
HQMumbai, India, India
Websitesunpharma.com
LinkedInCompany Page
Therapeutic Focus
Specialty PharmaceuticalsPsychiatryDermatologyOphthalmology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Metabolic & Endocrine
Nephrology
Metabolic & Endocrine
Diabetes Mellitus
GL0034Phase 2
Nephrology
Renal Insufficiency
GL0034Phase 1
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)